Last updated: May 27, 2026
ENTOCORT EC (budesonide) suppliers: Who manufactures the active ingredient, branded drug product, and key excipient systems
Executive summary: ENTOCORT EC (budesonide) is a controlled, branded oral corticosteroid formulation with supply split across (1) budesonide API suppliers and (2) finished-dose manufacturers for the extended-release capsule. Public-facing supplier visibility is strongest for the finished product on FDA labeling, and for the API via global chemical vendor catalogs and DMF-referenced supply chains. Without the specific market (NDA vs. country-specific label), strength (3 mg), pack, and whether the question targets API vs. finished capsules vs. packaging components, a complete, verifiable “supplier list” cannot be produced.
Which companies supply ENTOCORT EC capsules (3 mg budesonide extended-release) in the US?
Featured snippet answer: Finished-dose ENTOCORT EC supply is governed by the holder of the approved NDA and by any contracted contract manufacturing organizations (CMOs) listed on labeling for the marketed product. A reliable supplier list requires the specific FDA label/packager/marketer data for the exact strength and dosage form.
What does the US ENTOCORT EC label typically disclose about manufacturing?
- Applicant/labeler identity tied to the NDA holder.
- Manufacturing site(s) and/or packager/labeler information for the marketed capsule product.
- Submission-driven details such as release testing sites may appear in FDA databases, not always in public label text.
What distribution model drives ENTOCORT EC supplier visibility?
- Labeler and NDA holder can differ from the manufacturing site.
- CMOs can change without changing the NDA holder.
- Different lots may ship from different sites, affecting “supplier” interpretation.
Who supplies the ENTOCORT EC active pharmaceutical ingredient (budesonide API)?
Featured snippet answer: Budesonide API supply is handled by global fine-chemical producers supplying multiple branded and generic steroid products. A “complete” API supplier map requires correlating the drug’s approved application and referenced DMFs with current commercial vendors.
How API suppliers are identified in practice
- API DMF references tied to the NDA for budesonide and the finished dosage.
- Contracting arrangements across multiple API sources to cover demand variability and regulatory supply.
- Inspection history and QMS certification, which is not fully visible without DMF and inspection details.
What excipient suppliers power ENTOCORT EC extended-release (EC) capsule systems?
Featured snippet answer: ENTOCORT EC is an enteric/extended-release capsule system that uses polymer and enteric coating excipient technologies. Excipient suppliers vary by coating chemistry, film-former systems, and encapsulation hardware, and are rarely enumerated in public label text.
Which excipient categories matter for EC capsule performance
- Extended-release polymer system for release modulation
- Enteric-coating film components to protect the budesonide from gastric conditions
- Capsule shell materials (typically hard gelatin or alternatives depending on regulatory and supply)
- Plasticizers, glidants, and lubricants used in encapsulation blends
- Colorants and imprinting inks where applicable
How many ENTOCORT EC manufacturing sites supply the market and how are they contracted?
Featured snippet answer: The number of manufacturing sites is determined by regulatory approvals and historical supplement filings covering manufacturing changes, and it varies over time. A current count requires pulling the most recent label manufacturing details and matching them to approved manufacturing sites.
What drives site changes in ENTOCORT EC supply
- Equipment qualification cycles and inspection outcomes
- Raw material supply continuity (API and coating polymers)
- Scale-up and tech-transfer changes after supplement approvals
Are there alternative suppliers for ENTOCORT EC equivalent products (budesonide ER capsules) in the same market?
Featured snippet answer: There are multiple budesonide extended-release capsule products by different manufacturers depending on jurisdiction and regulatory approval status. “Alternative suppliers” for the branded ENTOCORT EC product specifically still requires label-based identification of the marketer/manufacturer combination.
What typically differs across competing budesonide ER products
- Polymer system and release profile
- Particle engineering of API (micronization, milling grade)
- Coating process controls and dissolution specifications
- Capsule shell composition and printing system
What patent or regulatory constraints affect supply chain substitution for ENTOCORT EC?
Featured snippet answer: Regulatory constraints are driven by approved formulation and manufacturing controls, plus exclusivity and patent thickets that can delay generic or authorized substitutes. Supply chain substitution does not require a “patent supplier,” but it does require regulatory approval of the specific product configuration.
How regulatory status affects supplier switching
- If exclusivity blocks generic entry in a jurisdiction, branded supply remains dominant.
- Post-exclusivity, generic supplier availability increases but only for approved products.
- Even when generics exist, payer contracts can sustain branded purchasing.
Key Takeaways
- ENTOCORT EC “suppliers” split into (1) finished-dose capsule manufacturer and (2) budesonide API and excipient supply chain.
- Publicly verifiable supplier lists require the exact FDA label details for the 3 mg ENTOCORT EC capsule and linkage to current manufacturing and labeler sites.
- API and excipient suppliers change more frequently and are usually not fully disclosed outside DMF and internal procurement records.
- Without those exact label and application reference points, a complete, accurate supplier roster cannot be produced.
FAQs
- Does ENTOCORT EC list a specific manufacturer on the bottle label for the 3 mg capsule strength?
- How can budesonide API suppliers be traced to ENTOCORT EC through DMF references?
- Do EC capsule excipient suppliers change between lots, and how is that controlled?
- Are there authorized budesonide extended-release capsule alternatives that can replace ENTOCORT EC by formulation?
- What regulatory events (supplements, manufacturing site changes) most often trigger ENTOCORT EC supply chain updates?
References
(No sources were cited because the requested “suppliers” list cannot be completed with verifiable public label, FDA application, DMF, or manufacturing-site data in the information provided.)
